# A Study of MT-2111 in Patients With Relapsed/Refractory DLBCL

Source: https://onco.cc/trials/nct05658562/  
OnCo record `nct05658562` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Loncastuximab tesirine in diffuse large b-cell lymphoma, run by Tanabe Pharma Corporation, active and no longer recruiting.

## Summary

A Study of MT-2111 in Patients With Relapsed/Refractory DLBCL is a phase 1/2 interventional study registered as NCT05658562 by Tanabe Pharma Corporation, with 46 participants enrolled, started 2023-01-30 and due to reach its primary completion in 2028-08. Interventions recorded: MT-2111. Conditions listed: Diffuse Large B-Cell Lymphoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05658562
- Phase: 1/2
- Setting: A Phase I/II Open-Label Study of MT-2111 in Patients With Relapsed/Refractory DLBCL
- Sponsor: Tanabe Pharma Corporation
- Enrolled: 46

## Sources

- ClinicalTrials.gov NCT05658562: https://clinicaltrials.gov/study/NCT05658562

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/)
- drugs: [Loncastuximab tesirine](https://onco.cc/drugs/zynlonta/)

---
JSON: https://onco.cc/api/v1/entities/nct05658562.json